EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Lonza Group (0QNO) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Lonza Group CHF 161, price CHF 566, upside -71.6%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · GB · Home Switzerland · ISIN CH0013841017

LG Some data Oct 1, 2026

Lonza Group

0QNO · LSE

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value CHF 160.73 · Strongly overvalued (−71.6%)
!Quality 52/100
!Expensive Growth (revenue 5y +7.7 %/yr)
!Loss-making · -1.6% net margin (TTM)
!Low debt · negative free cash flow
!0.9% dividend yield · Token dividend
!Moderate moat 48/100
!Evidence only medium, so the estimate is less certain
Watch Lonza Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 763.75 CHF 307.66 Fair Value CHF 160.73 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.

How to read this chart

60‑month range CHF 307.66 – CHF 763.75 · fair‑value band CHF 125.64 – CHF 204.15 · the CHF 566.00 price screens above the CHF 160.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments.

Show more

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Stock analysis

Lonza Group (0QNO) currently trades at CHF 566.00, while our model-based Fair Value estimate is CHF 160.73, 71.6% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of CHF 293.03 per share, and 0 of the 8 models we run sit above the CHF 566.00 price.

Bear case: the Dividend Discount group reads lowest at CHF 56.06, and 8 of the 8 models stay below the price. Evidence for this calculation is medium.

Scenario range: CHF 125.64 (bear) to CHF 204.15 (bull), the price of CHF 566.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Lonza Group reported revenue of CHF 6.5B in FY2025 versus CHF 5.4B in FY2021, a compound +4.8%/yr. Reported net income was −CHF 275M in FY2025.

Key figures

Market cap CHF 39.7B · P/E ratio 0.1 · P/S ratio 5.20 · EPS (TTM) CHF 39.52 · Dividend yield 0.9% · Net margin −4.2% · Return on equity 12.9% · Return on assets (EBIT) 5.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 5% below its 52-week high and 22% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −72%, 0QNO screens richer than that median.

Fair Value models

Bear CHF 125.64 Fair Value CHF 160.73 Bull CHF 204.15
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (CHF 26.11 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV CHF 130.64 CHF 155.81 CHF 177.83 74
ROIC Compounder CHF 132.65 CHF 172.25 CHF 222.09 72
EV/EBITDA CHF 264.48 CHF 359.43 CHF 454.37 67
All 8 models by family
Earnings-Based
EPV CHF 130.64 CHF 155.81 CHF 177.83 74
Dividend Discount
Gordon GGM CHF 34.54 CHF 71.82 CHF 113.94 66
DDM Multi-Stage CHF 34.54 CHF 56.06 CHF 75.38 66
Multiples
EV/EBIT CHF 214.68 CHF 293.03 CHF 371.37 66
EV/EBITDA CHF 264.48 CHF 359.43 CHF 454.37 67
EV/Revenue CHF 147.40 CHF 219.29 CHF 291.18 53
Asset-Based
NCAV (Graham) CHF 61.36 CHF 82.23 CHF 122.72 54
Economic Profit
ROIC Compounder CHF 132.65 CHF 172.25 CHF 222.09 72

Open the full fair value analysis →

Notify me when 0QNO reaches fair value

Put 0QNO on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 52/100

Of which business quality 49 · Market factors (momentum, volatility) 59

Profitability 12
Margins and returns on capital today
Quality Growth 54
Are margins and returns improving?
Cashflow 24
Earnings quality: real cash, not paper profit
Fin. Strength 66
Balance sheet, leverage, solvency risk
Investment 62
Disciplined investing over empire-building
Low Volatility 77
Calm price path (market factor)
Momentum 48
Price trend over the last 3–12 months (market factor)
52W Momentum 60
Distance to the 52-week high (market factor)
Net Issuance 98
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−0.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Start year 2020 (pandemic). Over 10 years: +5.6% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
20.8% (2020) → 21.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

0QNO screens overvalued: fair value 72% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Lonza Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 136 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 52 · Below median
Fair Value upside −72.2% · Bottom 25%
Profitability
Return on equity (TTM) 12.9% · Top 25%
Return on assets 5.4% · Above median
Net margin (TTM) −1.6% · Below median
Operating margin (TTM) 23.4% · Top 25%
Growth and dividend
Revenue growth 11.2% · Above median
Dividend yield (TTM) 0.9% · Below median
Balance sheet
Debt / equity 0.25× · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (TTM) 0.1× · Cheapest 25%
P/B 4.83× · Priciest 25%
P/S (TTM) 6.42× · Priciest 25%
EV/EBITDA 19.1× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $675.05 $686.04 +2%
Danaher Corporation DHR $221.55 $209.18 −6%
WuXi AppTec Co 603259 ¥162.40 ¥178.64 +10%
Agilent Technologies, Inc A $175.03 $64.17 −63%
IQVIA Holdings IQV $270.37 $297.41 +10%
Waters Corporation WAT $433.54 $106.46 −75%
Illumina, Inc ILMN $271.90 $295.60 +9%
IDEXX Laboratories, Inc IDXX $533.44 $495.84 −7%
Mettler-Toledo International Inc MTD $1,512 $644.24 −57%
Quest Diagnostics Incorporated DGX $237.62 $171.69 −28%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lonza Group · Fair Value
CHF 160.73 −72%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Lonza Group Fair Value". https://www.fairvalue-calculator.com/stock/0QNO

Frequently asked questions

Is Lonza Group (0QNO) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of CHF 160.73 versus a price of CHF 566.00, about −72% upside (overvalued).
What is the fair value of 0QNO?
Our model-based fair value for Lonza Group is CHF 160.73 (as of Oct 1, 2026), built from audited fundamentals. The current price: CHF 566.00.
What is the quality score of 0QNO?
Lonza Group has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lonza Group (0QNO)?
Our model-based price target is the fair value of CHF 160.73 (as of Oct 1, 2026) from 8 valuation models. Cautious scenario CHF 125.64, optimistic scenario CHF 204.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Lonza Group stock forecast for 2026?
Our models put fair value at CHF 160.73, about −72% upside versus a price of CHF 566.00 (overvalued). Cautious scenario CHF 125.64, optimistic scenario CHF 204.15. The calculation is refreshed regularly with new filings.
What is the revenue of Lonza Group (0QNO)?
Lonza Group reported trailing-twelve-month revenue of about CHF 6.9B (latest available figure, as of Oct 1, 2026).
Does Lonza Group pay a dividend?
Lonza Group currently shows a dividend yield of about 0.88% relative to its recent price (as of Oct 1, 2026).
What is the intrinsic value of Lonza Group (0QNO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lonza Group it is CHF 160.73 per share (as of Oct 1, 2026), against a price of CHF 566.00. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Lonza Group stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 0QNO trades above its calculated fair value: price CHF 566.00, fair value CHF 160.73, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0QNO?
No. The price is what the market pays today (CHF 566.00); the fair value is what the company's own numbers justify (CHF 160.73). For Lonza Group the two are CHF 405.27 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lonza Group worth?
The market values Lonza Group at about CHF 39.7B (market capitalisation, as of Oct 1, 2026). Per share that is CHF 566.00; our models calculate a fair value of CHF 160.73 per share.
What do the bullish and bearish scenarios say about 0QNO?
Our models span a range for Lonza Group: cautious scenario CHF 125.64, base CHF 160.73, optimistic CHF 204.15 per share (as of Oct 1, 2026, price CHF 566.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0QNO?
Lonza Group trades at a price-to-earnings ratio of 0.1 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 160.73 is built from several models across several years. Other multiples: P/B 4.8, P/S 6.4, EV/EBITDA 19.1.
How solid is the balance sheet of Lonza Group (0QNO)?
Balance-sheet figures for Lonza Group (as of Oct 1, 2026): return on equity 12.9%, debt of 0.25 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 0QNO from its 52-week high?
Lonza Group trades at CHF 566.00, about 5% below its 52-week high of CHF 593.71 and 22% above the low of CHF 464.93 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 160.73 is for.
Which stocks are comparable to Lonza Group?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lonza Group stock attractive at the current price?
The data as of Oct 1, 2026: price CHF 566.00, calculated fair value CHF 160.73 (−72%), Quality Score 52/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0QNO calculated?
We run Lonza Group through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 160.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Lonza Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lonza Group (0QNO)?
The closing price on Oct 2, 2026 was CHF 566.00. Our model-based fair value is CHF 160.73, about −72% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lonza Group right now?
The price sits above even our optimistic bull case (CHF 204.15). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Lonza Group (0QNO) come from?
Earnings per share at Lonza Group grew +6.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.0 %, EBIT margin +0.4 %, tax rate +0.2 %, residual (interest, one-offs) +3.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Lonza Group

How large is the market capitalisation of Lonza Group (0QNO)?
The market capitalisation of Lonza Group is CHF 39.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lonza Group (0QNO)?
The price-to-sales ratio of Lonza Group is 5.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lonza Group (0QNO)?
Earnings per share at Lonza Group are CHF 39.52 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Lonza Group (0QNO)?
The dividend yield of Lonza Group is 0.9% (payout 12.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Lonza Group (0QNO)?
The net margin of Lonza Group is −4.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lonza Group (0QNO)?
The return on equity (ROE) of Lonza Group is 12.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lonza Group (0QNO)?
On an EBIT basis the return on assets of Lonza Group is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lonza Group (0QNO)?
The operating margin of Lonza Group is 23.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lonza Group (0QNO)?
Revenue at Lonza Group is growing +11.2% versus a year earlier (3y avg +1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lonza Group (0QNO)?
Earnings per share at Lonza Group are growing +39.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Lonza Group (0QNO) generate?
The free cash flow of Lonza Group is −CHF 204M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lonza Group (0QNO) carry?
The net debt of Lonza Group is CHF 3.5B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Lonza Group in the live analysis

One click puts Lonza Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.